Extended Collaboration with Crop Protection Company

Nanologica has signed an agreement for continued collaboration with the global agricultural company that Nanologica has been working with. The extended agreement includes the formulation of another new active ingredient for plant protection using Nanologica’s technology. The value of the agreement amounts to approximately MSEK 1,3.   

In September 2017, Nanologica entered into an agreement with a global agricultural company specialized in crop protection, with the purpose of improving the formulation of an active ingredient for crop protection. The original agreement has been extended on several occasions.

The newly signed agreement entails an extended collaboration where a new active ingredient for crop protection will be formulated using Nanologica’s technology platform NLAB Silica™. The purpose is to control the release of the ingredient, thus decrease the amount of substance used in field. The new agreement stretches over approximately six months and the value amounts to approximately MSEK 1,3.

The challenges within crop protection are huge and we believe our technology has the possibility to solve several of the problems the industry faces. By using similar strategies to those used in formulation of pharmaceutical products, it is possible to dramatically reduce waste and environmental pollution. We see a great potential in our technology within this area, and we are able to provide the technology in an industrial scale, as we are scaling up our production of silica to ton scale.”, Prof. Adam Feiler, CTO of Nanologica comments.

Of the previously formulated ingredients, one has moved into small-scale laboratory studies and one is moving into field studies, whilst one of the first the projects for one of the previously formulated ingredients has been closed.


For further information, please contact:

Johanna Johansson, IR Nanologica

Ph: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com


About Nanologica AB (publ)

Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.